PMID- 30804429
OWN - NLM
STAT- MEDLINE
DCOM- 20191209
LR  - 20220416
IS  - 1532-1827 (Electronic)
IS  - 0007-0920 (Print)
IS  - 0007-0920 (Linking)
VI  - 120
IP  - 7
DP  - 2019 Apr
TI  - Breast cancer mortality in synchronous bilateral breast cancer patients.
PG  - 761-767
LID - 10.1038/s41416-019-0403-z [doi]
AB  - BACKGROUND: Evidence suggests that patients with synchronous bilateral breast 
      cancer (SBBC), diagnosed within 4 months, have an inferior prognosis compared to 
      unilateral breast cancer (UBC) patients. Using data from nationwide Danish 
      clinical databases, this cohort study investigated whether the inferior prognosis 
      could be explained by SBBC patients having a more aggressive disease, or whether 
      the prognosis could be explained by the fact that they have two simultaneous 
      cancers. METHODS: Patients were diagnosed from 1999-2015. The main outcome was 
      excess mortality, subtracting background population mortality from observed 
      mortality. Differences between SBBC and UBC patients were evaluated by rate 
      ratios (RR) and estimated by Poisson regression. RESULTS: In total, 1214 SBBC and 
      59 177 UBC patients were included. SBBC patients had a significantly higher 
      excess mortality than UBC patients after adjustment for age and period 
      (RR = 1.73; 95% CI:1.44-2.08; p < 0.01) and after adjusting for characteristics 
      of the worst tumour as traditionally done (RR = 1.31; 95% CI:1.08-1.57; 
      p = 0.01). However, adjusting for characteristics of both tumours, using a more 
      advanced competing risks model, no difference was observed (RR = 1.01; 95% 
      CI:0.83-1.22; p = 0.93). CONCLUSIONS: Our study does not support that the 
      inferior prognosis in SBBC patients is due to having more aggressive tumours per 
      se, but rather the combined effect of having two simultaneous cancers.
FAU - Mejdahl, Mathias Kvist
AU  - Mejdahl MK
AD  - Department of Breast Surgery, Herlev and Gentofte Hospital, Copenhagen University 
      Hospital, Herlev, Denmark. mathias.kvist.mejdahl@regionh.dk.
AD  - Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark. 
      mathias.kvist.mejdahl@regionh.dk.
FAU - Wohlfahrt, Jan
AU  - Wohlfahrt J
AD  - Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark.
FAU - Holm, Marianne
AU  - Holm M
AD  - Danish Cancer Society Research Center, Copenhagen, Denmark.
FAU - Balslev, Eva
AU  - Balslev E
AD  - Department of Pathology, Herlev Hospital, Copenhagen University Hospital, Herlev, 
      Denmark.
FAU - Knoop, Ann Soegaard
AU  - Knoop AS
AD  - Department of Oncology, Rigshospitalet, Copenhagen University Hospital, 
      Copenhagen, Denmark.
FAU - Tjonneland, Anne
AU  - Tjonneland A
AD  - Danish Cancer Society Research Center, Copenhagen, Denmark.
AD  - Institute of Public Health, University of Copenhagen, Copenhagen, Denmark.
FAU - Melbye, Mads
AU  - Melbye M
AD  - Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark.
AD  - Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
AD  - Department of Medicine, Stanford University School of Medicine, Stanford, CA, 
      USA.
FAU - Kroman, Niels
AU  - Kroman N
AD  - Department of Breast Surgery, Herlev and Gentofte Hospital, Copenhagen University 
      Hospital, Herlev, Denmark.
AD  - Danish Cancer Society, Copenhagen, Denmark.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190226
PL  - England
TA  - Br J Cancer
JT  - British journal of cancer
JID - 0370635
SB  - IM
MH  - Adult
MH  - Aged
MH  - Breast Neoplasms/*mortality
MH  - Carcinoma/*mortality
MH  - Case-Control Studies
MH  - Denmark
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Mortality
MH  - Neoplasms, Multiple Primary/*mortality
MH  - Prognosis
MH  - Unilateral Breast Neoplasms/*mortality
PMC - PMC6461871
COIS- The authors declare no competing interests.
EDAT- 2019/02/26 06:00
MHDA- 2019/12/18 06:00
PMCR- 2020/02/26
CRDT- 2019/02/27 06:00
PHST- 2018/10/02 00:00 [received]
PHST- 2019/01/24 00:00 [accepted]
PHST- 2019/01/24 00:00 [revised]
PHST- 2019/02/26 06:00 [pubmed]
PHST- 2019/12/18 06:00 [medline]
PHST- 2019/02/27 06:00 [entrez]
PHST- 2020/02/26 00:00 [pmc-release]
AID - 10.1038/s41416-019-0403-z [pii]
AID - 403 [pii]
AID - 10.1038/s41416-019-0403-z [doi]
PST - ppublish
SO  - Br J Cancer. 2019 Apr;120(7):761-767. doi: 10.1038/s41416-019-0403-z. Epub 2019 
      Feb 26.